NHI · Insider Trading
National Health Investors
Every open-market purchase and sale reported by NHI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-30 | Christian Ken Maingot | Chief Operating Officer | A | +2,370 | — |
| 2026-06-15 | Robert A McCabe Jr | Director | Buy | +890 | +$63.77K |
| 2026-06-09 | James R Jobe | Director | G | −225 | — |
| 2026-06-05 | D. Eric Mendelsohn | CEO and President | Buy | +1,500 | +$103.26K |
| 2026-05-07 | John L Spaid | CFO/EVP Finance | F | −314 | −$22.95K |
| 2026-05-07 | David L Travis | SVP/Chief Accounting Officer | F | −282 | −$20.61K |
| 2026-05-07 | D. Eric Mendelsohn | CEO and President | F | −394 | −$28.80K |
| 2026-03-30 | John L Spaid | CFO/EVP Finance | A | +5,072 | — |
| 2026-03-30 | Kevin Carlton Pascoe | Chief Investment Officer | A | +4,726 | — |
| 2026-03-05 | Tracy M J Colden | Director | A | +1,268 | — |
| 2026-03-05 | Elizabeth Jackson Blankenship | SVP, Legal Affairs | A | +2,420 | — |
| 2026-03-05 | James R Jobe | Director | A | +1,268 | — |
| 2026-03-05 | Robert A McCabe Jr | Director | A | +1,268 | — |
| 2026-03-05 | Kevin Carlton Pascoe | Chief Investment Officer | A | +5,072 | — |
| 2026-03-05 | Robert Chapin | Director | A | +1,268 | — |
| 2026-03-05 | Lilly Donohue | Director | A | +1,268 | — |
| 2026-03-05 | Candice W Todd | Director | A | +1,268 | — |
| 2026-03-05 | D. Eric Mendelsohn | CEO and President | MIXED | +13,812 | −$51.79K |
| 2026-03-05 | John L Spaid | CFO/EVP Finance | MIXED | +5,621 | −$123.51K |
| 2026-03-05 | David L Travis | SVP/Chief Accounting Officer | MIXED | +3,047 | −$35.65K |
| 2026-02-25 | David L Travis | SVP/Chief Accounting Officer | MIXED | +5,678 | −$295.56K |
| 2026-02-25 | John L Spaid | CFO/EVP Finance | MIXED | +1,952 | −$98.56K |
| 2026-02-25 | D. Eric Mendelsohn | CEO and President | MIXED | +2,948 | −$164.88K |
| 2026-02-25 | Kevin Carlton Pascoe | Chief Investment Officer | MIXED | +2,091 | −$86.04K |
| 2026-02-23 | Tracy M J Colden | Director | MIXED | +1,733 | −$48 |
| 2026-02-19 | D. Eric Mendelsohn | CEO and President | MIXED | +2,945 | −$173.95K |
| 2026-02-19 | James R Jobe | Director | MIXED | +1,942 | −$39 |
| 2026-02-17 | Robert A McCabe Jr | Director | MIXED | +1,820 | −$19 |
| 2026-02-13 | Kevin Carlton Pascoe | Chief Investment Officer | MIXED | +1,537 | −$88.01K |
| 2026-02-11 | David L Travis | SVP/Chief Accounting Officer | MIXED | +8,332 | −$436.81K |
| 2026-02-09 | Candice W Todd | Director | MIXED | +1,295 | −$83 |
| 2026-02-03 | Kristin Sallee Gaines | SVP/Chief Transaction Officer | M | +11,819 | −$608.47K |
| 2026-02-03 | Kevin Carlton Pascoe | Chief Investment Officer | MIXED | +3,398 | −$160.83K |
| 2026-01-29 | Robert G Adams | Director | MIXED | +3,907 | −$98 |
| 2026-01-20 | John L Spaid | CFO/EVP Finance | MIXED | +4,258 | −$175.02K |
| 2026-01-16 | Robert A McCabe Jr | Director | MIXED | +3,164 | −$66 |
| 2026-01-16 | D. Eric Mendelsohn | CEO and President | MIXED | +16,372 | −$569.54K |
| 2025-12-11 | Charlotte A Swafford | Director | MIXED | +17,173 | −$202 |
| 2025-11-24 | James R Jobe | Director | MIXED | +2,865 | −$72 |
| 2025-09-25 | David L Travis | SVP/Chief Accounting Officer | MIXED | +2,235 | −$70.85K |
| 2025-05-12 | Robert Chapin | Director | A | +10,000 deriv. | — |
| 2025-05-07 | John L Spaid | CFO/EVP Finance | F | −259 | −$19.69K |
| 2025-05-07 | D. Eric Mendelsohn | CEO and President | F | −394 | −$29.96K |
| 2025-04-01 | Robert G Adams | Director | MIXED | +12,065 | −$94 |
| 2025-03-05 | Candice W Todd | Director | A | +10,000 deriv. | — |
| 2025-03-05 | Kristin Sallee Gaines | SVP/Chief Transaction Officer | A | +4,000 | — |
| 2025-03-05 | David L Travis | SVP/Chief Accounting Officer | A | +5,500 | — |
| 2025-03-05 | John L Spaid | CFO/EVP Finance | A | +6,500 | — |
| 2025-03-05 | Tracy M J Colden | Director | A | — | — |
| 2025-03-05 | Robert A McCabe Jr | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert G Adams | Director | 342,096 | $22.91M |
| Charlotte A Swafford | Director | 170,185 | $11.40M |
| D. Eric Mendelsohn | CEO and President | 133,316 | $8.93M |
| Kristin Sallee Gaines | SVP/Chief Transaction Officer | 80,277 | $5.38M |
| Kevin Carlton Pascoe | Chief Investment Officer | 73,082 | $4.89M |
| John L Spaid | CFO/EVP Finance | 56,286 | $3.77M |
| Robert A McCabe Jr | Director | 44,158 | $2.96M |
| David L Travis | SVP/Chief Accounting Officer | 40,565 | $2.72M |
| James R Jobe | Director | 33,272 | $2.23M |
| Tracy M J Colden | Director | 12,858 | $860.97K |
| Candice W Todd | Director | 2,563 | $171.62K |
| Elizabeth Jackson Blankenship | SVP, Legal Affairs | 2,420 | $162.04K |
| Christian Ken Maingot | Chief Operating Officer | 2,370 | $158.70K |
| Robert Chapin | Director | 1,268 | $84.91K |
| Lilly Donohue | Director | 1,268 | $84.91K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NHI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.